Lineagen

Lineagen

Pioneering early diagnosis and intervention for autism and other complex diseases through innovative genetic testing and personalized support.

Founded 2002 51-200 employees Series C Total: $60.96M Biotechnology, Health Care

Lineagen is a biotechnology and healthcare startup that focuses on early diagnosis and intervention for complex diseases, particularly autism, through innovative genetic testing and personalized support. The company was founded in 2002 and has made significant strides in leveraging genetic profiles to improve outcomes for individuals affected by autism and other intricate diseases. Their specialized genetic testing and counseling services are tailored for early assessment of children at risk for developmental disorders, including autism spectrum disorders (ASDs). Lineagen's commercial approach is supported by extensive proprietary research into the genetic origins and diagnostic methods for major complex diseases such as autism, MS, and COPD. One of Lineagen's primary research advantages is its exclusive access to the Utah Population Database via the University of Utah, a premier biomarker discovery platform, which has enabled the discovery of more disease-related genes than any other institution globally. Notably, Lineagen secured a $12.17M Series C investment on 26 January 2015 from a consortium of investors including HealthQuest Capital, Kickstart Ventures, Signal Peak Ventures, Mesa Verde Venture Partners, Petra Capital Partners, Sanderling Ventures, University Growth Fund, PrairieGold Venture Partners, Archipel Capital, and Mountain Group Capital. Through its pioneering approach and focused research, Lineagen is at the forefront of transforming the landscape of early diagnosis and intervention for complex diseases, positioning itself as a compelling investment opportunity for venture capital firms seeking to support groundbreaking advancements in the biotechnology and healthcare sectors.

Funding Stage	Amount	Investors	Lead Investors	Date
Series C	$12.17M	10	HealthQuest Capital, Kickstart Ventures +8	26 Jan 2015
Series C	$3.50M	8	Kickstart Fund, Signal Peak Ventures +6	18 Dec 2013
Debt Financing	$11.59M	-		25 Apr 2013
Series B	$16.00M	4	Mesa Verde Venture Partners, Sanderling Ventures +2	04 Nov 2011
Series A	$10.80M	4	Mesa Verde Venture Partners, Sanderling Ventures +2	30 Aug 2010
Debt Financing	$1.10M	-		22 Jun 2010
Series A	$5.80M	3	Mesa Verde Venture Partners, Sanderling Ventures +1	31 Dec 2008

Funding Stage

Amount

Investors

Lead Investors

Date

Series C

$12.17M

HealthQuest Capital, Kickstart Ventures +8

26 Jan 2015

Series C

$3.50M

Kickstart Fund, Signal Peak Ventures +6

18 Dec 2013

Debt Financing

$11.59M

25 Apr 2013

Series B

$16.00M

Mesa Verde Venture Partners, Sanderling Ventures +2

04 Nov 2011

Series A

$10.80M

Mesa Verde Venture Partners, Sanderling Ventures +2

30 Aug 2010

Debt Financing

$1.10M

22 Jun 2010

Series A

$5.80M

Mesa Verde Venture Partners, Sanderling Ventures +1

31 Dec 2008

FAQ About Lineagen

Pioneering early diagnosis and intervention for autism and other complex diseases through innovative genetic testing and personalized support.

Lineagen was founded in 2002.

Lineagen operates in Biotechnology and Health Care. Its work centres on Genetic Testing, Healthcare Services, Autism Diagnosis and Complex Diseases.

Lineagen has approximately 51-200 employees.

Lineagen has completed 7 funding rounds, raising a total of $60.96M. The latest funding stage is Series C.

Top alternatives and competitors to Lineagen include Satoris Inc., MEDGENOME. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Lineagen and Satoris Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Lineagen

Funding Rounds & Investors (7)

Lineagen Alternatives & Competitors

FAQ About Lineagen